# China Glioblastoma Multiforme Market > China Glioblastoma Multiforme Market Research Report By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field (TTF) Therapy, Others) and By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 8.17% - **2024:** $ 220.57 Million - **2025:** $ 238.59 Million - **2035:** $ 523.31 Million - **Key Players:** Bristol-Myers Squibb (US), Merck & Co (US), Roche (CH), Novartis (CH), Eli Lilly and Company (US), Amgen (US), AstraZeneca (GB), Pfizer (US), Bayer (DE) **Report ID:** MRFR/HC/50496-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/china-glioblastoma-multiforme-market-52254 --- ## Market Summary ## **China Glioblastoma Multiforme Market Overview** As per MRFR analysis, the China Glioblastoma Multiforme Market Size was estimated at 162.55 (USD Million) in 2023. The China Glioblastoma Multiforme Market Industry is expected to grow from 176.4(USD Million) in 2024 to 425 (USD Million) by 2035. The China Glioblastoma Multiforme Market CAGR (growth rate) is expected to be around 8.322% during the forecast period (2025 - 2035). ## **Key China Glioblastoma Multiforme Market Trends Highlighted** The China Glioblastoma Multiforme market is undergoing significant trends that are influenced by a variety of key market drivers. The growing awareness and enhanced diagnostic capabilities within healthcare systems are significant drivers of the increasing incidence of glioblastoma multiforme in the region. Pharmaceutical companies and research institutions are forming partnerships to focus on the development of novel therapies and drug delivery systems that are specifically designed for the treatment of glioblastoma.  Furthermore, the Chinese government's dedication to improving oncological care by allocating resources and financing is fostering an environment that is conducive to innovation and intervention in cancer treatment. Opportunities in this market are becoming more evident, particularly for local biotech firms that are investigating innovative therapeutic avenues through gene therapy and immunotherapy. The potential for real-world data collection to further enhance treatment effectiveness and address unmet requirements in glioblastoma management is significant, given the extensive patient population of China. Additionally, government initiatives that are designed to enhance the infrastructure of healthcare offer companies the opportunity to collaborate with hospitals and specialized treatment centers, thereby facilitating patient access to clinical trials for innovative therapies. Global healthcare trends have been reflected in the increased emphasis on personalized medicine in the treatment of glioblastoma in recent market trends. The utilization of sophisticated technologies, including artificial intelligence, is currently being investigated in order to improve the precision of diagnostics and treatment planning. Furthermore, public awareness campaigns are gaining momentum, with the objective of educating patients about glioblastoma and the available treatment options, thereby facilitating early diagnosis and intervention. The dynamic nature of the China Glioblastoma Multiforme market is reflected in this evolving landscape, which is poised for continued growth and innovation in the years ahead. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ## **China Glioblastoma Multiforme Market Drivers** Rising Incidence of Glioblastoma Multiforme in China The increasing incidence of Glioblastoma Multiforme in China serves as a significant driver for the China Glioblastoma Multiforme Market Industry. According to the National Health Commission of China, the number of reported brain cancer cases has seen a steady increase over the last decade, with Glioblastoma accounting for approximately 15% of all brain tumor cases. A report indicated that there were about 39,000 new cases of brain cancer reported in China in 2021, highlighting the growing need for effective treatments and innovative therapies within the market. The Chinese government and various health organizations have been actively emphasizing the importance of cancer research and improving healthcare services, which in turn drives funding toward the development of targeted treatments for Glioblastoma Multiforme. This increasing cancer population prompts pharmaceutical companies to research and develop novel therapeutics, contributing to the expansion and growth of the market as patients seek advanced treatment options. Advancements in Treatment Technologies Innovative advancements in treatment technologies have been pivotal in enhancing the China Glioblastoma Multiforme Market Industry. Recent developments in precision medicine and targeted therapies have resulted in improved patient outcomes, with therapies like tumor-treating fields (TTFields) gaining popularity. Clinical trials conducted by institutions such as the Chinese Academy of Medical Sciences have shown promising results with novel therapeutic options that extend survival rates for patients with Glioblastoma Multiforme. As China invests in research and collaboration between academic and industrial sectors, advancements in treatment technologies can significantly impact the availability of new therapies for patients. Consequently, an increase in clinical trials and successful outcomes directly boosts pharmaceutical investment in the China Glioblastoma Multiforme Market, further propelling market growth. Growing Government Initiatives and Funding Government initiatives and increased funding directed towards cancer research play a crucial role in driving the China Glioblastoma Multiforme Market Industry. The Chinese government has launched various action plans aimed at controlling cancer prevalence, such as the National Cancer Control Plan, which aims to enhance early diagnosis, treatment, and prevention. Moreover, funding allocated for cancer research has seen a substantial increase, reaching over 30% in the past five years, according to the Ministry of Science and Technology in China. This financial support encourages both local and international companies to invest in drug development and novel procedures for treating Glioblastoma Multiforme. Such government backing is essential for fostering innovation and research partnerships, thereby stimulating market growth and resulting in improved therapeutic solutions for patients. ## **China Glioblastoma Multiforme Market Segment Insights** ### **Glioblastoma Multiforme Market Treatment Type Insights** The Treatment Type segment of the China Glioblastoma Multiforme Market includes various therapeutic approaches pivotal in managing this aggressive cancer. Surgery remains a crucial first-line intervention, often aimed at maximizing tumor resection to alleviate symptoms and extend survival. This method is significant as it lays the groundwork for subsequent treatments and is typically complemented by Radiation Therapy, which utilizes high-energy beams to target any remaining cancer cells, thereby enhancing overall treatment efficacy. Chemotherapy has gained attention for its role in systemic treatment, utilizing drug regimens aimed at attacking rapidly dividing cancer cells, contributing notably to patient outcomes.  Immunotherapy is experiencing a growing presence in this segment, as it employs the body’s immune system to combat glioblastoma, offering innovative therapeutic options that can lead to improved long-term survival rates. The Tumor Treating Field (TTF) Therapy represents another emerging modality, which uses electric fields to disrupt cancer cell division, showcasing its effectiveness in combination with other treatment methods, especially in recurrent cases. Other treatment options may include targeted therapies and supportive care strategies, which are essential for addressing the side effects of more aggressive treatments and improving the patient's quality of life. The interplay between these various treatment modalities reflects a trend toward personalized medicine in China, driven by advancements in technology and deepening understanding of cancer biology.  Overall, the Treatment Type segment is characterized by continual innovation and adaptation, responding to increasing incidence rates and the need for effective therapeutic strategies. With supportive infrastructure from the Chinese government and growing investment in health care, this market segment is expected to evolve, integrating new advancements and improving patient care for those battling glioblastoma multiforme. The dynamic landscape of treatment options fosters a competitive environment, emphasizing the need for ongoing Research and Development to enhance efficacy and address challenges in therapy delivery, ultimately aiming to improve survival outcomes and the well-being of affected individuals in China. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ### **Glioblastoma Multiforme Market End User Insights** The end-user segment of the China Glioblastoma Multiforme Market encompasses various crucial entities, primarily Hospitals and Clinics, Ambulatory Surgical Centers, and other healthcare facilities. Hospitals and Clinics are pivotal in providing comprehensive care and advanced treatment options for glioblastoma multiforme patients, being equipped with specialized medical staff and technologies that are essential for effective management of the disease. Ambulatory Surgical Centers play a significant role by offering outpatient surgical procedures, which contribute to a more efficient treatment process and lower costs for patients. The growing preference for outpatient care and minimally invasive surgeries is driving this segment's expansion. Moreover, the increasing awareness and improving healthcare infrastructure in China further boost the capabilities of all end users, ensuring patients have better access to the latest treatment methodologies. Overall, the end-user segment not only facilitates patient care but also enhances the overall treatment landscape within the China Glioblastoma Multiforme Market, meeting the rising demands for specialized medical services in this area. **China Glioblastoma Multiforme Market Key Players and Competitive Insights:** The China Glioblastoma Multiforme Market is witnessing considerable developments as pharmaceutical companies strive to address the urgent needs for effective treatment options within this challenging medical landscape. The increasing incidence of glioblastoma multiforme, a highly aggressive form of brain cancer, has heightened competition among players in the market. With ongoing innovations in drug therapies, especially targeted and immunotherapy approaches, various manufacturers are pursuing research and collaborations to enhance their product portfolios.  Strategic alliances, mergers, and acquisitions are common as companies seek to expand their market presence and improve the accessibility of advanced treatment solutions. The regulatory environment in China also plays a pivotal role in shaping competition, influencing product approval timelines, and determining market entry strategies.AstraZeneca holds a significant position in the China Glioblastoma Multiforme Market, backed by its robust research and development capabilities aimed at launching innovative cancer therapies. The company has made substantial investments in developing treatments that can effectively target glioblastoma multiforme, distinguishing itself with promising clinical trial outcomes.  AstraZeneca's emphasis on patient-centric approaches and collaboration with local healthcare providers enhances its ability to cater to the unique needs of Chinese patients. Its existing portfolio of cancer drugs, along with ongoing clinical trials, positions AstraZeneca favorably in the market. The company's commitment to advancing oncology care through partnerships and specialized initiatives establishes a strong foundation to continue making inroads in the competitive landscape of glioblastoma treatments.Roche is another formidable player in the China Glioblastoma Multiforme Market, recognized for its pioneering contributions to oncology. With a comprehensive range of key products tailored for brain cancer treatment, Roche has established itself as a leader in innovative therapeutics. The company's strengths lie in its longstanding reputation for research excellence and its extensive pipeline of potential treatments for glioblastoma multiforme.  Roche has also engaged in strategic mergers and acquisitions that have expanded its capabilities and access to cutting-edge therapies. Collaborations with localized entities to facilitate quicker market entry and adherence to China's specific healthcare demands demonstrate Roche's adaptability and responsiveness. By leveraging its formidable presence and emphasizing tailored treatment solutions, Roche continues to enhance its foothold in the competitive landscape of the China Glioblastoma Multiforme Market. **Key Companies in the China Glioblastoma Multiforme Market Include:** **China Glioblastoma Multiforme Market Industry Developments** In recent months, the China Glioblastoma Multiforme Market has witnessed significant developments. AstraZeneca has introduced innovative therapies aimed at improving treatment outcomes for glioblastoma patients, while Roche continues to expand its portfolio in precision medicine to target this aggressive cancer type effectively. Merck and Co., along with Bristol Myers Squibb, have been enhancing their Research and Development focus, particularly surrounding immunotherapy options for glioblastoma, reflecting the growing emphasis on personalized medicine in oncology.  Moreover, China’s healthcare policies are increasingly supportive of advanced treatment methodologies, thereby bolstering industry growth.In terms of mergers and acquisitions, no major activity involving AstraZeneca, Roche, or other pharmaceutical giants such as GSK, Merck and Co., and Bristol Myers Squibb has been reported in the glioblastoma sector recently. However, Novartis and Eli Lilly have been active in collaborations aimed at enriching their treatment offerings. China’s market for glioblastoma therapies is anticipated to grow, driven by the country's increasing investment in cancer care and the push for innovative treatments, as evidenced by government initiatives focusing on oncology advancements over the past few years. ## **China Glioblastoma Multiforme Market Segmentation Insights** ### **Glioblastoma Multiforme Market Treatment Type****Outlook** ### **Glioblastoma Multiforme Market End User****Outlook** ## Market Drivers ### Rising Incidence Rates The glioblastoma multiforme market in China is experiencing growth due to the rising incidence rates of this aggressive brain tumor. Recent statistics indicate that the annual incidence of glioblastoma in China is approximately 2.5 per 100,000 individuals, which translates to thousands of new cases each year. This increasing prevalence is likely to drive demand for innovative treatment options and diagnostic tools within the glioblastoma multiforme market. As healthcare providers and researchers focus on addressing this growing challenge, investments in research and development are expected to rise, potentially leading to the introduction of novel therapies. Furthermore, the aging population in China may contribute to higher incidence rates, as older individuals are more susceptible to developing glioblastoma. This trend underscores the urgent need for effective treatment solutions in the glioblastoma multiforme market. ### Increased Awareness and Education Increased awareness and education regarding glioblastoma multiforme are pivotal drivers of the market in China. Efforts by healthcare organizations and advocacy groups to educate the public about the symptoms and risks associated with glioblastoma are leading to earlier diagnosis and treatment. This heightened awareness is crucial, as timely intervention can significantly impact patient outcomes. Moreover, educational initiatives targeting healthcare professionals are enhancing the understanding of glioblastoma management, thereby improving treatment protocols. As awareness grows, more patients are likely to seek medical attention, which could lead to an increase in the demand for therapies and diagnostic tools within the glioblastoma multiforme market. The potential for improved patient outcomes through education underscores the importance of these initiatives in shaping the future landscape of the market. ### Government Initiatives and Funding Government initiatives aimed at improving cancer care in China are playing a crucial role in shaping the glioblastoma multiforme market. The Chinese government has increased funding for cancer research and treatment programs, with a reported investment of over $1 billion in recent years. These initiatives are designed to enhance access to advanced therapies and improve patient outcomes. Additionally, the establishment of specialized cancer centers and the promotion of public awareness campaigns are likely to facilitate early diagnosis and treatment of glioblastoma. As a result, the glioblastoma multiforme market is expected to benefit from enhanced infrastructure and resources, ultimately leading to better management of this challenging disease. The commitment to cancer care by the government may also encourage private sector investment, further stimulating growth in the glioblastoma multiforme market. ### Technological Advancements in Treatment Technological advancements in treatment modalities are significantly impacting the glioblastoma multiforme market in China. Innovations such as precision medicine, which tailors treatment based on individual genetic profiles, are becoming increasingly prevalent. The introduction of advanced surgical techniques, including minimally invasive procedures, has also improved patient outcomes. Furthermore, the development of novel drug delivery systems, such as nanoparticles, is enhancing the efficacy of existing therapies. According to recent estimates, the market for targeted therapies in China is projected to reach $500 million by 2027, reflecting the growing interest in personalized treatment approaches. These technological advancements not only improve survival rates but also contribute to a more favorable quality of life for patients. As such, the glioblastoma multiforme market is expected to see continued growth driven by these innovations. ### Collaboration Between Research Institutions Collaboration between research institutions and pharmaceutical companies is emerging as a key driver in the glioblastoma multiforme market. In China, partnerships aimed at accelerating research and development of new therapies are becoming more common. These collaborations facilitate the sharing of knowledge, resources, and expertise, which can lead to the discovery of innovative treatment options. For instance, joint ventures between academic institutions and biotech firms are focusing on the development of novel immunotherapies and targeted treatments. This collaborative approach not only enhances the pace of research but also increases the likelihood of successful clinical trials. As a result, the glioblastoma multiforme market is expected to benefit from a more robust pipeline of therapies, ultimately improving treatment options for patients. ## Future Outlook The [Glioblastoma Multiforme Market](https://www.marketresearchfuture.com/reports/glioblastoma-multiforme-market-12161) in China is projected to grow at 8.17% CAGR from 2025 to 2035, driven by advancements in treatment options and increasing patient awareness. **New opportunities:** - Development of targeted therapies for specific genetic mutations. - Expansion of telemedicine services for remote patient monitoring. - Investment in AI-driven diagnostic tools for early detection. By 2035, the market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Treatment Type: Surgery (Largest) vs. Immunotherapy (Fastest-Growing) In the China glioblastoma multiforme market, the Treatment Type segment reveals a diverse distribution of shares. Surgery holds the largest market share, being the primary intervention for glioblastoma, while Radiation Therapy and Chemotherapy follow closely, with significant utilization rates. Immunotherapy and Tumor Treating Field (TTF) Therapy, although currently smaller in share, are gaining traction as innovative treatment options and are set to alter the landscape of treatment strategies. Growth trends within this segment are driven by numerous factors, including advancements in medical technology, increased research funding for glioblastoma treatments, and a growing emphasis on personalized medicine approaches. The emergence of Immunotherapy and TTF Therapy is particularly noteworthy, as they represent significant breakthroughs in treatment modalities, allowing for better patient outcomes and potentially reshaping the standard care protocols in disease management. Surgery (Dominant) vs. Immunotherapy (Emerging) Surgery is the dominant treatment option in the market, often a first-line approach for glioblastoma due to its effectiveness in tumor debulking. It provides immediate results but is limited by factors such as tumor location and patient condition. Immunotherapy, on the other hand, is an emerging segment, leveraging the body's immune system to combat cancer. This treatment is characterized by its innovative nature and potential for long-term management of glioblastoma. Such treatments are gaining acceptance owing to their ability to target specific cancer cells while minimizing harm to healthy tissue. The growing understanding of biomarkers and personalized treatment plans further enhances the market potential for Immunotherapy, making it a key focus for future research and development in treating glioblastoma. ### By End User Type: Hospitals & Clinics (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing) In the China glioblastoma multiforme market, Hospitals & Clinics account for the largest share due to their extensive resources and established networks for patient treatment. Ambulatory Surgical Centers are gaining a sizable share and are recognized for their efficiency and patient-centric approaches. Additionally, the "Others" segment includes various emerging and supportive healthcare facilities that cater to specific patient needs, albeit with a smaller market presence compared to the two largest segments. The growth of this segment is propelled by factors like increasing patient awareness, advancements in surgical techniques, and the rising number of healthcare facilities. The shift towards minimally invasive procedures has made Ambulatory Surgical Centers more appealing, with their ability to provide quality care at lower costs. Furthermore, the integration of innovative technologies in these setups is contributing to their rapid expansion. Hospitals & Clinics (Dominant) vs. Ambulatory Surgical Centers (Emerging) Hospitals & Clinics serve as the dominant force in the China glioblastoma multiforme market, primarily due to their comprehensive capabilities in providing extensive patient care, from diagnosis to treatment. These institutions benefit from established infrastructure, experienced medical personnel, and the ability to conduct complex procedures. Conversely, Ambulatory Surgical Centers are emerging as a preferred choice for many patients due to their focus on outpatient care, which reduces the need for lengthy hospital stays. Their rise is supported by increasing investments and technologies that enhance surgical outcomes and patient satisfaction, positioning them as a viable alternative in the treatment landscape. ## Competitive Benchmarking The glioblastoma multiforme market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansion. Key players such as Bristol-Myers Squibb (US), Roche (CH), and Novartis (CH) are actively pursuing strategies that emphasize research and development, particularly in the realm of targeted therapies and immuno-oncology. These companies are not only focusing on enhancing their product portfolios but are also investing in collaborations with local biotech firms to leverage regional expertise and accelerate the development of novel treatments. This collective approach appears to foster a dynamic environment where competition is driven by the need for advanced therapeutic options and improved patient outcomes.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure is moderately fragmented, with several players vying for market share, yet the influence of major companies remains substantial. This competitive framework allows for a diverse range of treatment options, although it also necessitates that companies remain agile in their operational strategies to respond to evolving market demands. In October Roche (CH) announced a strategic partnership with a leading Chinese biotech firm to co-develop a novel immunotherapy for glioblastoma multiforme. This collaboration is expected to leverage Roche's extensive research capabilities alongside local insights, potentially accelerating the drug's path to market. The strategic importance of this partnership lies in its potential to enhance Roche's competitive positioning in the region while addressing a critical unmet need in glioblastoma treatment. In September Novartis (CH) launched a new clinical trial for its innovative CAR-T cell therapy aimed at glioblastoma multiforme. This trial is significant as it represents a shift towards personalized medicine, which could redefine treatment paradigms in this challenging area. The implications of this development suggest that Novartis is committed to leading the charge in advanced therapeutic solutions, thereby strengthening its market presence. In August Bristol-Myers Squibb (US) expanded its operations in China by establishing a new research facility dedicated to oncology. This move is indicative of the company's long-term commitment to the region and its recognition of the growing demand for innovative cancer therapies. The establishment of this facility is likely to enhance BMS's research capabilities and foster collaborations with local institutions, thereby positioning the company favorably in the competitive landscape. As of November current trends in the glioblastoma multiforme market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are becoming more prevalent, as companies recognize the value of collaborative innovation in addressing complex medical challenges. Looking ahead, it is anticipated that competitive differentiation will evolve, with a pronounced shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This evolution underscores the necessity for companies to adapt and innovate continuously in order to maintain a competitive edge in the market. ## Recent News & Developments In recent months, the China Glioblastoma Multiforme Market has witnessed significant developments. AstraZeneca has introduced innovative therapies aimed at improving treatment outcomes for glioblastoma patients, while Roche continues to expand its portfolio in precision medicine to target this aggressive cancer type effectively. Merck and Co., along with Bristol Myers Squibb, have been enhancing their Research and Development focus, particularly surrounding immunotherapy options for glioblastoma, reflecting the growing emphasis on personalized medicine in oncology.  Moreover, China’s healthcare policies are increasingly supportive of advanced treatment methodologies, thereby bolstering industry growth.In terms of mergers and acquisitions, no major activity involving AstraZeneca, Roche, or other pharmaceutical giants such as GSK, Merck and Co., and Bristol Myers Squibb has been reported in the glioblastoma sector recently. However, Novartis and Eli Lilly have been active in collaborations aimed at enriching their treatment offerings. China’s market for glioblastoma therapies is anticipated to grow, driven by the country's increasing investment in cancer care and the push for innovative treatments, as evidenced by government initiatives focusing on oncology advancements over the past few years. ## Report Scope | MARKET SIZE 2024 | 220.57(USD Million) | | --- | --- | | MARKET SIZE 2025 | 238.59(USD Million) | | MARKET SIZE 2035 | 523.31(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.17% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Bristol-Myers Squibb (US), Merck & Co (US), Roche (CH), Novartis (CH), Eli Lilly and Company (US), Amgen (US), AstraZeneca (GB), Pfizer (US), Bayer (DE) | | Segments Covered | Treatment Type, End User Type | | Key Market Opportunities | Advancements in targeted therapies and immunotherapies present growth opportunities in the glioblastoma multiforme market. | | Key Market Dynamics | Rising investment in Research and Development for innovative therapies drives growth in the glioblastoma multiforme market. | | Countries Covered | China | ## Frequently Asked Questions **Q: What was the overall market valuation for glioblastoma multiforme in 2024?** A: The overall market valuation for glioblastoma multiforme was $220.57 Million in 2024. **Q: What is the projected market valuation for glioblastoma multiforme by 2035?** A: The projected market valuation for glioblastoma multiforme is $523.31 Million by 2035. **Q: What is the expected CAGR for the glioblastoma multiforme market during the forecast period 2025 - 2035?** A: The expected CAGR for the glioblastoma multiforme market during the forecast period 2025 - 2035 is 8.17%. **Q: Which treatment type had the highest valuation in 2024?** A: Chemotherapy had the highest valuation among treatment types, reaching $150.0 Million in 2024. **Q: What is the valuation range for radiation therapy in the glioblastoma multiforme market?** A: The valuation range for radiation therapy is between $50.0 Million and $120.0 Million. **Q: Which end user type accounted for the largest market share in 2024?** A: Hospitals & Clinics accounted for the largest market share, with a valuation between $110.0 Million and $260.0 Million. **Q: What is the valuation range for immunotherapy in the glioblastoma multiforme market?** A: The valuation range for immunotherapy is between $30.0 Million and $80.0 Million. **Q: Which companies are considered key players in the glioblastoma multiforme market?** A: Key players in the glioblastoma multiforme market include Bristol-Myers Squibb, Merck & Co, Roche, Novartis, Eli Lilly and Company, Amgen, AstraZeneca, Pfizer, and Bayer. **Q: What is the valuation range for tumor treating field (TTF) therapy?** A: The valuation range for tumor treating field (TTF) therapy is between $20.0 Million and $50.0 Million. **Q: What is the valuation range for ambulatory surgical centers in the glioblastoma multiforme market?** A: The valuation range for ambulatory surgical centers is between $60.57 Million and $140.0 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-glioblastoma-multiforme-market-52254*